Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: monoclonal antibody therapeutics - Agenus

Next Previous
Search
Drug Profile

Research programme: monoclonal antibody therapeutics - Agenus

Alternative Names: AGEN 2041; Checkpoint modulator antibodies - 4-Antibody/Ludwig Institute for Cancer Research; Checkpoint modulator antibodies - Agenus/Incyte; CPM antibodies - Agenus/Incyte; Cytotoxic T-lymphocyte antigen 4 inhibitor antibodies - Agenus/Recepta; PDCD 1 protein inhibitor antibodies - Agenus/Recepta

Latest Information Update: 23 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 4-Antibody; Ludwig Institute for Cancer Research
  • Developer Incyte Corporation
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; HAVCR2 protein inhibitors; OX40 receptor agonists; Programmed cell death 1 receptor antagonists; TNFRSF18 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 31 Oct 2022 Incyte Corporation intend to terminates its licence for OX40 program from October 2023
  • 28 Sep 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA
  • 01 Aug 2018 Preclinical trials in Solid tumours in USA (unspecified route) (Incyte Corporation pipeline, August 2018)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top